Achieve Life Sciences, Inc. (ACHV) Stock Score, Valuation & Financial Research

Achieve Life Sciences, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for ACHV

Achieve Life Sciences, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 8.09. These figures are a research snapshot, not a buy or sell recommendation.

What Achieve Life Sciences, Inc. does

Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid, which functions by engaging with nicotine receptors in the brain to lessen the intensity of nicotine withdrawal symptoms. The company holds licensing agreements with Sopharma AD and the University of Bristol. Its corporate headquarters are located in Vancouver, Canada.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Achieve Life Sciences is a late-stage clinical pharmaceutical company that does not currently generate revenue from product sales. Its business model focuses on the development and future commercialization of cytisinicline for nicotine dependence, relying on external funding and capital raises to finance research, clinical trials, and regulatory activities.

Products and services

  • Cytisinicline, a plant-based alkaloid drug candidate currently in clinical development for the treatment of nicotine dependence, including smoking and e-cigarette cessation.

Brands and product families

  • Cytisinicline — The company's sole product candidate for nicotine dependence treatment. Source

Customer types

Healthcare providers and patients seeking nicotine cessation treatments.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — Various third-party organizations providing non-clinical, clinical, and data management services. Source
  • Third-party manufacturers — Unnamed third-party manufacturers responsible for producing drug product for clinical trials. Source

Business relationships and partnerships

  • Adare Pharma Solutions — A U.S.-based manufacturer partnered with Achieve to manufacture cytisinicline drug product for potential commercial launch. Source

Business strengths to evaluate

  • Clinical development of cytisinicline for nicotine dependence Source
  • FDA Commissioner's National Priority Voucher designation Source

Business risks and research considerations

  • Lack of product revenue and history of operating losses Source
  • Dependence on a single product candidate, cytisinicline Source
  • Requirement for substantial additional capital to fund operations Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

ACHV financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 8.09
Market capitalization:
830.51M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -114.04M
Free cash flow:
USD -49.47M
Cash:
USD 47.96M
Total debt:
USD 14.95M
EPS:
USD -1.55

What stands out

  • Free cash flow is USD -49.47M, negative for the stored period.
  • The balance sheet shows USD 47.96M of cash versus USD 14.95M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a corporate distress warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 33.01M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for ACHV

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can ACHV fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is ACHV likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for ACHV to reach sustainable profitability?
  • What does the current corporate distress warning mean for the reliability or interpretation of ACHV's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research ACHV

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.